CD33 and acute myeloid leukemia: The resulting CAR33-KLRC1ko-NK cells showed superior cytotoxic capacity against CD33+/HLA-E+ target cells as compared to either CAR33-NK cells or KLRC1ko-NK cells against AML cell lines, patient-derived primary AML blast cells ex vivo and in a murine xenograft AML model in vivo.